2022 AGM – Meeting Recording

November 11, 2022November 15, 2022 Alterity Therapeutics

Post navigation

Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease
ShareCafe Investor Webinar Recording
ShareCafe Investor Webinar Presentation
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

2022 AGM – Meeting Recording

Related Posts

Dr David Stamler Biotech Showcase Presentation

Alterity presents clinical data on PBT434 at the 2019 MDS Congress

Prana Alzheimer’s disease Development Plan Update